(MedPage Today) — The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced.
Approval of the injectable…
Source link : https://www.medpagetoday.com/dermatology/generaldermatology/116179
Author :
Publish date : 2025-06-20 20:47:00
Copyright for syndicated content belongs to the linked Source.
